Contact Us
Drug Search Results
More Filters [+]

MULTIMERIC-001

Alternative Names: multimeric-001, multimeric001, multimeric 001
Latest Update: 2024-04-18
Latest Update Note: PubMed Publication

Product Description

a BiondVax-developed universal influenza vaccine as a standalone vaccine or as a primer to H5N1 influenza vaccine (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28296763/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BiondVax
Company Location: JERUSALEM L3 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MULTIMERIC-001

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HHSN272201300015I

P2

Completed

Influenza, Human

2019-01-14

2015-001979-46

P2

Completed

Influenza, Human

2016-10-06

BVX006

P2

Completed

Influenza, Human

2015-03-01

BVX-005

P2

Completed

Influenza, Human

2012-01-01

Recent News Events

Date

Type

Title

04/18/2024

PubMed

 Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron-Associated Hospitalization in Children and Adolescents - United States, 2021-2023.

04/17/2023

PubMed

 Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions